Vivek Patel

ORCID: 0000-0001-8583-1548 · 1 paper in corpus

article 2006

GMA161 Treatment of Refractory ITP: Efficacy of Fcγ-RIII Blockade.

·doi:10.1182/blood.v108.11.1074.1074

Abstract Background: GMA161 is a humanized version of a monoclonal anti-Fcγ-RIII antibody, 3G8, that was in clinical trial in the second half of the 1980s. Infusion of 25 mg of 3G8 (0.25–0.5mg/kg) resulted in transient but dramatic response…